Clinical Research Directory
Browse clinical research sites, groups, and studies.
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Sponsor: Jirair Krikor Bedoyan
Summary
This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency.
Official title: An Open Label, Exploratory, Proof-of Concept Study of Triheptanoin as Treatment for Patients With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Key Details
Gender
All
Age Range
1 Year - 17 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2024-07-11
Completion Date
2029-06-30
Last Updated
2026-02-17
Healthy Volunteers
No
Interventions
Triheptanoin
Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
Locations (1)
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States